MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 23.03.2026
Arbutus Biopharma Corporation EV 2011-2026 | ABUS
EV Jährlich Arbutus Biopharma Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 847 M | 818 M | 457 M | 449 M | 339 M | 283 M | 160 M | 196 M | 279 M | 185 M | 141 M | 533 M | 143 M | 31 M | 23.8 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 847 M | 23.8 M | 326 M |
EV anderer Aktien in der Pharmaeinzelhändler
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
436 M | - | 1052.0 % | $ 415 M |  USA |
 |
Anika Therapeutics
ANIK
|
300 M | $ 14.21 | -0.42 % | $ 208 M | USA |
 |
Aeterna Zentaris
AEZS
|
5.52 M | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
417 M | - | -0.23 % | $ 916 M | USA |
 |
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B |  France |
 |
Aileron Therapeutics
ALRN
|
33.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
329 M | $ 3.35 | -2.62 % | $ 295 M | USA |
 |
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
849 M | $ 216.26 | -0.83 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
4.79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.92 B | $ 19.12 | -0.57 % | $ 894 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
169 M | $ 0.62 | 2.14 % | $ 7.1 M |  Israel |
 |
AgeX Therapeutics
AGE
|
6.28 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-13.2 M | - | -24.86 % | $ 820 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
4.38 B | $ 46.45 | -0.91 % | $ 4.18 B |  Schweiz |
 |
Acasti Pharma
ACST
|
24 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
125 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
38.2 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Avenue Therapeutics
ATXI
|
-1.23 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
1.11 B | $ 1.4 | -0.36 % | $ 357 M | Britain |
 |
Exelixis
EXEL
|
11.9 B | $ 41.13 | -0.69 % | $ 11.2 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | Israel |
 |
ChemoCentryx
CCXI
|
91.4 M | - | - | $ 3.74 B | USA |
 |
Aytu BioScience
AYTU
|
-15.2 M | $ 2.63 | - | $ 16.5 M | USA |
 |
Fulcrum Therapeutics
FULC
|
-180 M | $ 6.64 | -3.63 % | $ 421 K | USA |
 |
Atreca
BCEL
|
94.8 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
445 M | - | -4.8 % | $ 255 M | USA |
 |
Genmab A/S
GMAB
|
27 B | $ 25.59 | -0.35 % | $ 16.5 B | Danmark |
 |
Grifols, S.A.
GRFS
|
11.8 B | $ 7.64 | -0.72 % | $ 6.83 B |  Spain |
 |
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | Germany |
 |
BeiGene, Ltd.
BGNE
|
-720 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Halozyme Therapeutics
HALO
|
12 B | $ 61.68 | -1.88 % | $ 7.39 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
1.26 B | $ 26.99 | -2.21 % | $ 1.55 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
77.1 M | - | -74.18 % | $ 955 K | USA |
 |
ImmuCell Corporation
ICCC
|
54.7 M | $ 6.43 | 0.31 % | $ 52.5 M | USA |
 |
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | USA |
 |
Immatics N.V.
IMTX
|
503 M | $ 9.32 | -2.0 % | $ 586 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
15.6 B | $ 69.48 | -1.85 % | $ 11.1 B | USA |
 |
Innate Pharma S.A.
IPHA
|
259 M | $ 1.33 | -2.92 % | $ 235 M | France |
 |
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
22.8 M | - | 1.93 % | $ 17.4 M | USA |